Table of Content

1. 1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. United States Prostate Cancer Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing)
5.2.2. By Application (Diagnostics Biomarkers, Prognostics Biomarkers)
5.2.3. By End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Others)
5.2.4. By Region (Northeast Region, Midwest Region, South Region, West Region)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Biomarker Type
5.3.2. By Application
5.3.3. By End User
5.3.4. By Region
6. Northeast United States Prostate Cancer Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Biomarker Type
6.2.2. By Application
6.2.3. By End User
7. Midwest United States Prostate Cancer Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Biomarker Type
7.2.2. By Application
7.2.3. By End User
8. South United States Prostate Cancer Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Biomarker Type
8.2.2. By Application
8.2.3. By End User
9. West United States Prostate Cancer Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Biomarker Type
9.2.2. By Application
9.2.3. By End User
10. Market Dynamics
10.1. Drivers
10.1.1. Rising prevalence of prostate cancer
10.1.2. Growing geriatric population
10.1.3. Government Initiatives related to Prostate Cancer
10.1.4. Technological Advancement
10.1.5. Recent Development
10.2. Challenges
10.2.1. High Probability of False Positives during Prostate Cancer Testing
11. Market Trends & Developments
12. United States Economic Profile
13. Competitive Landscape
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.5.1. F. Hoffmann-La Roche Ltd (FOUNDATION MEDICINE, INC.).
13.5.2. Siemens Healthcare GmbH
13.5.3. OPKO Health, Inc. (GenPath)
13.5.4. Myriad Genetics Inc.
13.5.5. NeoGenomics Laboratories
13.5.6. Danaher. (Beckman Coulter, Inc.)
13.5.7. Agilent Technologies, Inc.
13.5.8. Abcam plc.
13.5.9. Bio-Techne. (ExoDx)
13.5.10. H.U. Group Holdings, Inc. (Fujeribio)
14. Strategic Recommendations